The Choice of Administration Options
Talk to your patients about the most convenient option for them
INSTRUCTIONS FOR USE:
Transitioning from IV therapy to SC administration
Patients with LN: Transition to subcutaneous therapy can be done any time after the patient completes the first 2 intravenous doses. Administer the first subcutaneous dose 1 to 2 weeks after the last intravenous dose. IV and SC are not to be used concurrently.
Did you know?
76% of patients with SLE taking BENLYSTA preferred administration with the Autoinjector over IV infusion*
* A follow-up survey was conducted in patients with SLE (N=43) who completed open-label, multi-dose, usability, tolerability, and safety study of subcutaneous (SC) belimumab where they were switched from IV or prefilled syringe belimumab to self-administered doses using the Autoinjector for 8 weekly doses. Patients (n=42) were asked, “What is your preference for receiving BENLYSTA: using the Autoinjector or IV?”
- The diluted solution of BENLYSTA should be administered by intravenous infusion over a period of 1 hour.
- BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis.
- BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.
- Do not administer as an intravenous push or bolus.